普洛药业(000739) - 2015 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2015 was CNY 4,337,941,187.73, representing a 2.48% increase compared to CNY 4,232,760,143.46 in 2014[16] - The net profit attributable to shareholders for 2015 was CNY 208,230,302.31, a decrease of 35.37% from CNY 322,164,386.53 in 2014[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 181,694,223.68, down 13.04% from CNY 208,948,158.21 in 2014[16] - The net cash flow from operating activities was CNY 441,161,691.40, a decline of 43.92% compared to CNY 786,637,638.17 in 2014[16] - Basic earnings per share for 2015 were CNY 0.18, a decrease of 40.00% from CNY 0.30 in 2014[16] - The total operating profit decreased to CNY 202,342,315.27 from CNY 343,065,395.27, representing a decline of approximately 41%[185] - Net profit for the period was CNY 208,230,302.31, down from CNY 326,717,096.85, indicating a decrease of about 36%[186] - The company's net profit margin decreased, with net profit not explicitly stated but indicated by the increase in operating costs outpacing revenue growth[184] Assets and Liabilities - The total assets at the end of 2015 were CNY 5,394,938,741.45, an increase of 6.58% from CNY 5,061,811,825.38 at the end of 2014[16] - Total liabilities rose to CNY 2,978,147,711.23, compared to CNY 2,755,867,206.12, indicating an increase of approximately 8.1%[177] - The company's cash and cash equivalents at the end of the period were CNY 49,287,613.61, compared to CNY 35,428,816.88 at the beginning of the year[179] - The total owner's equity at the end of the period was 91,030.22 million yuan, reflecting the company's financial stability[200] Revenue Sources - The pharmaceutical main business accounted for 99.70% of total revenue, with revenue of CNY 4,324,779,307.50, up 2.48% from CNY 4,220,257,955.60 in 2014[39] - Total revenue from sales of goods and services received was CNY 4,778,934,112.90, an increase from CNY 4,589,830,734.20, showing a growth of about 4%[191] Research and Development - The company completed 222 R&D projects in 2015, including 14 national-level projects and 94 provincial-level projects, indicating a strong commitment to innovation[35] - R&D investment increased by 15.80% to CNY 192,478,576.22, representing 4.44% of total operating revenue, up from 3.93% in 2014[46] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.55 per 10 shares, based on a total of 1,146,869,310 shares[5] - The cash dividend for 2015 represents 30.29% of the net profit attributable to shareholders, which is RMB 208,230,302.31[72] - The company has maintained a consistent cash dividend policy over the past three years, with a payout ratio around 30%[72] Market Position and Strategy - The company maintained stable market shares for key products, with some products like AVNA and Gitamycine experiencing growth rates exceeding 20%, while certain products saw a decline in sales[34] - The company established a strategic partnership with Zhejiang Huahai Pharmaceutical Co., Ltd. to expand domestic and international markets[35] - The company’s marketing network covers 32 countries and regions, enhancing its global reach[30] Compliance and Governance - The company has not disclosed any significant undisclosed information during the investor communications held in 2015[65] - The company reported no significant litigation or arbitration matters during the reporting period[87] - The independent directors have not raised any objections to company matters during the reporting period, indicating a consensus on governance practices[151] Employee and Management Information - The total number of employees in the company is 6,497, with 3,843 in production, 842 in sales, and 875 in technical roles[138] - The company has a salary system based on a combination of base salary and bonuses, reflecting industry standards and local economic conditions[134] - The independent directors receive an annual allowance of 50,000 RMB as per the shareholders' meeting resolution[134] Cash Flow and Investment Activities - The company reported a cash inflow of 212,577,618.98 yuan from operating activities, compared to 33,754,275.72 yuan in the previous year[195] - The total cash inflow from financing activities was 1,410,431,948.65 yuan, while the cash outflow was 1,367,816,493.60 yuan, resulting in a net cash flow of 42,615,455.05 yuan[194] - The total cash outflow from investment activities was 200,745,750.00 yuan, leading to a net cash flow from investment activities of -73,965,750.00 yuan[196] Internal Control and Audit - The company has not identified any significant internal control deficiencies during the reporting period, indicating effective internal governance[158] - The internal control audit report issued a standard unqualified opinion, confirming effective internal controls over financial reporting[160]